Blog

Nelson Advisors has been referenced in the Centre for Aging + Brain Health Innovation 'AgeTech Insights: The Digest'Source: <a href="https://www.cabhi.com/en/knowledge-insights/agetech-insights/reports-articles/agetech-insights-the-digest-2026">https://www.cabhi.com/en/knowledge-insights/agetech-insights/reports-articles/agetech-insights-the-digest-2026</a>How do Canadians really feel about growing older? What do they need to support them as they age? Are there tools or technologies they use—or wish existed—to improve the aging experience? &nbsp;As Canada’s population ages rapidly, these questions are more important than ever. The AgeTech Insights team at the Centre for Aging + Brain Health Innovation (CABHI), powered by Baycrest, is working to answer them.&nbsp;In Canada, nearly 20% of the population is already over the age of 65, and this number is projected to triple by 2050. Globally, by 2030, an additional 300 million people are expected to be over the age of 65compared to 2023. As populations age, the prevalence of age-related cognitive decline and disease, including dementia, increases. Currently, over 770,000 Canadians are living with dementia, and by 2050, that number is expected to increase to nearly 1.7 million. &nbsp;Our AgeTech Insights team of experts has recently been focused on better understanding how Canadians experience aging—particularly in relation to cognition and brain health— and how technology is, or could be, used to support aging with purpose, fulfilment, and dignity.&nbsp;Key insights at-a-glance&nbsp; Canadians are overwhelmingly aware of cognitive changes that occur as they age and are concerned about their brain health&nbsp; Comfort levels with technology are high, but not when it comes to using it to support brain health&nbsp; Current technologies do not meet needs and do not engage users during the design process&nbsp;Opportunities to meet user needs with agetech&nbsp; As we continue to experience major demographic shifts worldwide, questions pertaining to the types of technology older Canadians want and the gaps in agetech offerings are not only top of mind but also top of market. In 2025 alone, agetech companies raised over $700M, and over the next four years, the broader dementia treatment market, which includes technology-supported solutions, is expected to grow 8% year-over-year. &nbsp;Evidence shows that concerns about cognitive decline throughout the aging experience are present, and adoption of everyday technologies is already high, but the available solutions on the market are not tailored to the needs of the target audience. For market growth to translate into lasting impact, emerging technologies must be designed with older persons—the end users—at the core. &nbsp;There is a massive opportunity to develop agetech solutions that thoughtfully address the needs of older persons while also contributing to economic growth in Canada.&nbsp;<a href="https://www.healthcare.digital/single-post/dementia-care-technology-healthtech-market-to-watch-in-2025">https://www.healthcare.digital/single-post/dementia-care-technology-healthtech-market-to-watch-in-2025﻿</a>

Nelson Advisors referenced in the Centre for Aging + Brain Health Innovation 'AgeTech Insights: The Digest'

Nelson Advisors has been referenced in the Forbes article 'Kintsugi CEO Says Building AI For Healthcare Is Financially Unsustainable For Startups'Building artificial intelligence (AI) for healthcare has never been more technically feasible — or more financially punishing. As generative AI innovation and adoption accelerate, even startups with clinically validated models, peer-reviewed trials, and enterprise demand are discovering that scientific proof no longer guarantees commercial survival. Regulatory clearance does.Kintsugi, a mental health AI startup that developed clinically validated voice biomarkers capable of detecting depression and anxiety from short clips of free-form speech, is the latest example. After raising roughly $30 million, completing years of clinical research, and conducting a pivotal study of about 1,600 participants over four years, the California-based company recently shut down its operations.“When you're building at the intersection of AI and a highly regulated healthcare space, venture investors still expect you to be at $100 million in ARR by year ten—and now, with the acceleration driven by AI and LLMs, they expect that by year three or five. But in healthcare, you can’t even sell your commercial product until you are FDA cleared,” Grace Chang, founder and CEO of Kintsugi, told me. “That fundamental mismatch between venture timelines and regulatory timelines creates enormous structural tension for startups like ours.”Source: <a href="https://www.forbes.com/sites/victordey/2026/02/17/kintsugi-ceo-says-building-ai-for-healthcare-is-financially-unsustainable-for-startups/" data-mce-href="https://www.forbes.com/sites/victordey/2026/02/17/kintsugi-ceo-says-building-ai-for-healthcare-is-financially-unsustainable-for-startups/">https://www.forbes.com/sites/victordey/2026/02/17/kintsugi-ceo-says-building-ai-for-healthcare-is-financially-unsustainable-for-startups/</a>The decision reflects both a mission-driven exit and a structural warning for the AI healthcare sector. Recent industry data shows healthcare AI shutdowns rose more than 25% between 2024 and 2025 amid a broader funding contraction, with mental health AI companies facing particularly intense scrutiny around clinical efficacy and regulatory compliance. New legislations have further tightened oversight. The state of Illinois enacted the Wellness and Oversight for Psychological Resources Act (HB 1806) in Aug. 2025, signed by Gov. J.B. Pritzker, prohibiting the use of AI in therapy and psychotherapy services. Industry analysts estimate that only about 16% of mental health AI tools have undergone rigorous clinical testing, raising concerns among regulators about real-world effectiveness.<a href="https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026" data-mce-href="https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026">https://www.healthcare.digital/single-post/why-do-founders-and-investors-fear-an-ai-bubble-could-burst-in-healthcare-in-2026</a>

Nelson Advisors referenced in Forbes article 'Kintsugi CEO Says Building AI For Healthcare Is Financially Unsustainable For Startups'

The market for Practice Management Software (PVS - Praxisverwaltungssoftware, also referred to as Arztinformationssysteme or AIS) in Germany is undergoing a profound structural transformation. Long characterised by legacy local architectures, fragmented market shares and a highly protective regulatory environment, the sector is experiencing rapid disruption driven by mandatory digitisation laws, the emergence of cloud-native and artificial-intelligence-native platforms, and aggressive consolidation backed by private equity and venture capital.&nbsp; The German practice management software market is experiencing a significant shift. Driven by mandatory regulatory requirements such as the DigiG and the ePA, healthcare providers are forced to upgrade their technology infrastructure.This has created an opening for agile, cloud-native challengers to compete with established legacy providers. For corporate incumbents, protecting market share requires moving away from proprietary, closed databases toward open, API-driven architectures and cloud hosting. At the same time, venture-backed startups are targeting high-friction areas like clinical documentation and billing automation.&nbsp; Ultimately, the players that succeed will be those that can successfully navigate Germany's complex regulatory environment while delivering simple, user-friendly, and reliable software that reduces the daily administrative burden on clinicians.Read the 'The German Healthcare Practice Management Software Market is undergoing a profound structural transformation (Praxisverwaltungssoftware, Arztinformationssysteme)' report in full here..<a href="https://www.healthcare.digital/single-post/the-german-healthcare-practice-management-software-market-is-undergoing-a-profound-structural-transf" data-mce-href="https://www.healthcare.digital/single-post/the-german-healthcare-practice-management-software-market-is-undergoing-a-profound-structural-transf">https://www.healthcare.digital/single-post/the-german-healthcare-practice-management-software-market-is-undergoing-a-profound-structural-transf</a>

Praxisverwaltungssoftware and Arztinformationssysteme: the German Healthcare Practice Management Software Market is experiencing a significant shift

The execution of private equity buy-and-build strategies within the highly fragmented European medical technology distribution sector has reached a new level of scale and complexity. On June 2nd 2026, Nordic private equity firm Axcel announced the simultaneous acquisition of four distinct regional distributors to establish Sanviva, a newly consolidated European medical device distribution network. By pulling Apodan (Denmark), PartnerMed (Norway), AllweCare Medical (Netherlands), and XboXLab (Sweden) into a unified platform, Axcel is building a single, pan-European gateway. &nbsp;&nbsp; This consolidated platform, headquartered in Copenhagen, Denmark, establishes an immediate footprint across six European countries: Denmark, Sweden, Norway, Finland, Belgium and the Netherlands, operating with an initial workforce of approximately 60 employees.&nbsp; &nbsp;&nbsp; The overarching strategy of the platform, under the leadership of newly appointed Group CEO Andreas von Scholten, is to act as a highly specialised local commercialisation partner for global medical device manufacturers and original equipment manufacturers (OEMs).&nbsp; &nbsp;&nbsp; By providing direct access to multiple regional healthcare markets through a single partnership, Sanviva removes the need for OEMs to build out expensive, country-by-country sales forces or independently navigate local regulatory and public tendering frameworks.Read the 'The Sanviva Case Study: Operational and Regulatory Dynamics of Axcel’s Pan-European MedTech Distribution Consolidation' report in full here..<a href="https://www.healthcare.digital/single-post/the-sanviva-case-study-operational-and-regulatory-dynamics-of-axcel-s-pan-european-medtech-distribu" data-mce-href="https://www.healthcare.digital/single-post/the-sanviva-case-study-operational-and-regulatory-dynamics-of-axcel-s-pan-european-medtech-distribu">https://www.healthcare.digital/single-post/the-sanviva-case-study-operational-and-regulatory-dynamics-of-axcel-s-pan-european-medtech-distribu</a>

Sanviva and Axcel: Platform Synergies and Value Creation Playbook

Dexcom’s acquisition of Nutrisense marks a deliberate move to expand its target market from traditional, high-risk diabetes management into preventative care, weight management and general wellness.&nbsp; &nbsp;&nbsp; Historically, Dexcom’s primary revenue engine has been prescribing CGMs to patients with Type 1 diabetes and insulin-dependent Type 2 diabetes. While highly profitable, this market represents only a fraction of the global population experiencing metabolic dysfunction, pre-diabetes, or general insulin resistance. &nbsp;&nbsp; Nutrisense has established itself as a leading player in the direct-to-consumer metabolic wellness space by bundling Dexcom's hardware with a comprehensive software app and access to human Registered Dietitians. The platform caters to individuals focused on optimising nutrition, athletic performance and body composition. By acquiring Nutrisense, Dexcom achieves several key strategic objectives, including the direct integration of dietitian services, transitioning to a high-margin subscription model and establishing preventative health pathways before patients escalate to insulin dependency. &nbsp;&nbsp; The transaction is expected to close in the coming weeks, subject to customary closing conditions and regulatory approvals, though the specific financial terms remain undisclosed. The programs offered by Nutrisense will continue to restrict eligibility, excluding individuals who take insulin or those who have a history of problematic hypoglycemia, thereby preserving its focus on early-stage intervention. &nbsp;&nbsp; This acquisition is flanked by two major announcements at ADA 2026 that reinforce Dexcom's pivot toward earlier-stage intervention. First, findings from the CONNECT study, a randomised controlled trial co-authored by Thomas W. Martens, MD, from the International Diabetes Center, were presented on June 6th, 2026, showcasing the clinical benefits of Dexcom CGM use in adults with Type 2 diabetes who do not use insulin. This trial has the potential to alter future clinical standards of care by proving that early CGM adoption improves glycemic control without pharmacological escalation. &nbsp;&nbsp; Second, Dexcom introduced a completely reimagined Stelo app experience, which received Food and Drug Administration clearance in May 2026. Select Stelo users were granted early access on June 5th, 2026, ahead of a full rollout scheduled for later in the summer.&nbsp; &nbsp;&nbsp; Stelo is Dexcom's over-the-counter platform designed for adults with Type 2 diabetes who do not use insulin, as well as general wellness seekers. The updated application launches with proactive artificial intelligence coaching, pattern recognition, and personalised weekly summaries designed to reveal the direct connection between glucose levels and physical sensations. Jake Leach, President and CEO of Dexcom, emphasised that these initiatives are designed to build a connected ecosystem that delivers real-time observations, personalised support, and behavioural coaching.Read the 'The Paradigm Shift in Metabolic Health: Dexcom’s Strategic Acquisition of Nutrisense and the Convergence of Biosensing, AI and Coaching' report in full here.. <a href="https://www.healthcare.digital/single-post/the-paradigm-shift-in-metabolic-health-dexcom-s-strategic-acquisition-of-nutrisense-and-the-converg">https://www.healthcare.digital/single-post/the-paradigm-shift-in-metabolic-health-dexcom-s-strategic-acquisition-of-nutrisense-and-the-converg</a>

The Strategic Imperative Behind Dexcom’s Acquisition of Nutrisense

The European HealthTech sector has seen a surge of momentum, highlighted by a massive growth round addressing one of the industry's biggest bottlenecks: administrative fragmentation and clinical workflow inefficiencies.The major developments shaping the European HealthTech landscape include:1. Semble Secures £30M Series C to Redefine Care OrchestrationThe biggest headline comes from London-based Semble, which closed a £30 Million Series C funding round led by European growth investor Revaia, with participation from Partech, Mercia Ventures, and Octopus Ventures.The Problem: Healthcare providers across Europe are heavily weighed down by disjointed, legacy technology systems. This fragmentation burns out clinicians and slows down patient care.The Solution: Semble operates an open, interoperable clinical platform that integrates with over 1,200 external tools (including diagnostics, billing, and lab systems). It acts as a unified "system of action" to manage entire patient journeys and streamline workflows.The Scale: The platform has already powered care for over 10 million patients (roughly 1 in 6 people in the UK).The fresh capital will be used to scale their AI-driven care orchestration and expand heavily into large healthcare groups across the UK and France.2. Strong Funding Momentum Backs Digital Health &amp; AIA newly released sector report by Tech.eu (European Tech: The Big Picture) confirms that capital is concentrating into larger, highly commercialised rounds across biotech, medtech, and AI-enabled healthcare.Investor Takeaway: While Series A deals are still robustly supporting early clinical platform development, late-stage capital is aggressively backing companies that have proven clinical utility and are actively scaling internationally.3. The Clinical AI Benchmarking ShiftWhile big-tech general AI models grab global headlines, European specialised medical AI labs are demonstrating superior clinical accuracy. Danish AI lab Corti recently made waves as its domain-specific medical coding model, Symphony, outperformed mainstream models like OpenAI and Anthropic by more than 25% in independent clinical accuracy benchmarks.&nbsp;This highlights a growing trend: European health systems are leaning toward hyper-specialised, highly regulated vertical AI solutions over general LLMs to ensure patient safety and compliance.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk&gt;&gt;&gt;&gt;The European MedTech sector has experienced a highly active week, dominated by fallout from the MedTech Forum 2026 in Stockholm, a major legislative clash over AI regulation, and fresh structural updates designed to make Europe a more attractive market for medical hardware and device innovation.The most significant MedTech developments shaping the market include:1. The AI Act "Digital Omnibus" BacklashA major point of friction reached a head following the political agreement on the Digital Omnibus, which amends the landmark EU AI Act.The Conflict: MedTech Europe (the region's primary trade association) had heavily lobbied for medical technologies to have a single, sector-specific compliance pathway managed entirely under existing medical regulations. Instead, the final deal confirms that AI-enabled medical devices will remain subject to parallel, overlapping high-risk requirements from both the AI Act and the Medical Devices Regulation (MDR).The Industry Stance: Industry leaders expressed deep disappointment, stating the agreement adds "an unnecessary layer of complexity to a sector already operating under some of the world's most stringent oversight." Attention has now shifted toward using the ongoing, targeted revision of the MDR to salvage a workable solution and prevent severe market launch delays for smart medical devices.2. Push for Radical Overhaul of the MDR &amp; IVDRAt the MedTech Forum, the overarching theme among European device CEOs was a collective anxiety over market conditions and a demand for structural predictability.Following the European Commission’s newly proposed revision package for the MDR and In Vitro Diagnostics Regulation (IVDR), MedTech Europe submitted its comprehensive 39-page position paper. The industry is aggressively backing proposals to simplify the rules, which the EU Parliament projects could save up to €3.3 billion annually(including €2.4 billion in wiped-out administrative bloat).Key areas of focus during this week's legislative debate include:The EMA Innovation Pilot: Industry leaders praised the European Medicines Agency's newly launched innovative device pilot for Class III and implantable devices, which acts as a precursor to a formal, US-style "breakthrough device" pathway.Regulatory Sandboxes: The introduction of EU-level regulatory sandboxes is being fast-tracked, allowing companies to test cutting-edge software and AI hardware in real-world environments without immediately hitting a wall of full conformity assessments.3. Shift in Public Procurement Strategy: "Buy Better, Not Just European"A significant strategic pivot is underway regarding how European hospitals buy medical equipment. MedTech Europe CEO Oliver Bisazza issued a strong warning to EU policymakers against falling into raw protectionism.Currently, many European healthcare systems rely on price-only procurement, which heavily favors cheap imports and stifles local, high-quality hardware innovation. The industry is mobilising to pressure member states to rewrite procurement rules to prioritise value, clinical outcomes, and long-term supply resilience over the lowest sticker price.4. The UK Responds with the "International Reliance" PathwayAs the EU scrambles to fix its slow approval pipelines, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has moved decisively to capture market share.The MHRA published its draft Medical Devices (Amendment) Regulations 2026. Crucially, it introduces an international reliance pathway. This allows medical device manufacturers who have already secured regulatory clearance in trusted global markets (like the US FDA) to access the Great Britain market via a drastically fast-tracked, simplified review process. It represents a direct bid by the UK to attract global MedTech developers who are weary of Brussels' bureaucratic delays.Nelson Advisors &gt; European MedTech and HealthTech Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk" data-mce-href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital" data-mce-href="https://www.healthcare.digital">https://www.healthcare.digital&nbsp;</a>Nelson Advisors publish Europe’s leading HealthTech and MedTech M&amp;A Newsletter every week, subscribe today! <a href="https://lnkd.in/e5hTp_xb">https://lnkd.in/e5hTp_xb&nbsp;</a>Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>Meet Nelson Advisors @ 2026 EventsDigital Health Rewired &gt; March 2026 &gt; Birmingham, UK&nbsp;NHS ConfedExpo &nbsp;&gt; June 2026 &gt; Manchester, UK&nbsp;HLTH Europe &gt; June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare &gt; July 2026, New York, USABits &amp; Pretzels &gt; September 2026, Munich, Germany &nbsp;World Health Summit 2026 &gt; October 2026, Berlin, GermanyHealthInvestor Healthcare Summit &gt; October 2026, London, UK&nbsp;HLTH USA 2026 &gt; October 2026, USABarclays Health Elevate &gt; October 2026, London, UK&nbsp;Web Summit 2026 &gt; November 2026, Lisbon, Portugal &nbsp;MEDICA 2026 &gt; November 2026, Düsseldorf, GermanyVenture Capital World Summit &gt; December 2026 Toronto, Canada

Nelson Advisors

Blog

Nelson Advisors referenced in the Centre for Aging + Brai...

Nelson Advisors referenced in Forbes article 'Kintsugi CE...

Praxisverwaltungssoftware and Arztinformationssysteme: th...

Sanviva and Axcel: Platform Synergies and Value Creation ...

The Strategic Imperative Behind Dexcom’s Acquisition of N...

This Week in European MedTech and HealthTech: 5th June 2026